Novel Direct Anticoagulants and Atherosclerosis

Area of Science:

• Biochemistry
• Cardiovascular Biology
• Inflammation Research

Background:

• Coagulation factors interact with cellular pathways beyond hemostasis, impacting inflammatory signaling.
• These interactions are implicated in the development and progression of atherosclerosis.
• Experimental models suggest coagulation protease inhibitors may slow atherosclerosis, but clinical evidence is lacking.

Purpose of the Study:

• To review the role of coagulation factors in atherosclerosis pathogenesis.
• To evaluate the translational evidence for anticoagulants in atherosclerosis management.
• To identify future research directions for novel anticoagulants in cardiovascular disease.

Main Methods:

• Literature review of experimental and clinical studies on coagulation factors and atherosclerosis.
• Analysis of data on the effects of coagulation protease inhibitors in animal models.
• Evaluation of existing clinical trial data for anticoagulants in atherosclerosis.

Main Results:

• Coagulation factors modulate endothelial, smooth muscle, and inflammatory cells, contributing to atherosclerosis.
• Animal studies demonstrate that coagulation protease inhibitors can attenuate atherosclerosis progression.
• Current clinical data do not support anticoagulants as an effective add-on therapy for atherosclerosis.

Conclusions:

• Coagulation factors play a significant role in atherosclerosis beyond their hemostatic function.
• Translational evidence from animal models does not fully translate to clinical benefits of anticoagulants.
• Further clinical studies with refined patient selection are necessary to determine the role of novel direct anticoagulants in managing atherosclerosis.